[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EE05411B1 - Retseptori nukleiinhapped ja polpeptiidid - Google Patents

Retseptori nukleiinhapped ja polpeptiidid

Info

Publication number
EE05411B1
EE05411B1 EEP200300107A EEP200300107A EE05411B1 EE 05411 B1 EE05411 B1 EE 05411B1 EE P200300107 A EEP200300107 A EE P200300107A EE P200300107 A EEP200300107 A EE P200300107A EE 05411 B1 EE05411 B1 EE 05411B1
Authority
EE
Estonia
Prior art keywords
nucleic acids
receptor nucleic
pol peptides
pol
peptides
Prior art date
Application number
EEP200300107A
Other languages
English (en)
Estonian (et)
Inventor
M. Ambrose Christine
S. Thompson Jeffrey
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27499682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05411(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200300107A publication Critical patent/EE200300107A/xx
Publication of EE05411B1 publication Critical patent/EE05411B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
EEP200300107A 2000-09-18 2001-09-06 Retseptori nukleiinhapped ja polpeptiidid EE05411B1 (et)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23315200P 2000-09-18 2000-09-18
US23414000P 2000-09-21 2000-09-21
US26849901P 2001-02-13 2001-02-13
US31218501P 2001-08-14 2001-08-14
PCT/US2001/028006 WO2002024909A2 (fr) 2000-09-18 2001-09-06 Acides nucleiques et polypeptides de nouveau recepteur

Publications (2)

Publication Number Publication Date
EE200300107A EE200300107A (et) 2005-02-15
EE05411B1 true EE05411B1 (et) 2011-04-15

Family

ID=27499682

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300107A EE05411B1 (et) 2000-09-18 2001-09-06 Retseptori nukleiinhapped ja polpeptiidid

Country Status (34)

Country Link
US (8) US7112421B2 (fr)
EP (3) EP1842918B2 (fr)
JP (2) JP5904689B2 (fr)
KR (1) KR100935744B1 (fr)
CN (3) CN1940068A (fr)
AR (1) AR030760A1 (fr)
AT (2) ATE360070T1 (fr)
AU (2) AU2001288858B2 (fr)
BG (1) BG66208B1 (fr)
BR (1) BR0113921A (fr)
CA (1) CA2422622C (fr)
CY (2) CY1106708T1 (fr)
CZ (1) CZ299161B6 (fr)
DE (1) DE60128002T2 (fr)
DK (3) DK1352063T3 (fr)
EA (2) EA012833B1 (fr)
EE (1) EE05411B1 (fr)
ES (2) ES2388153T3 (fr)
GE (1) GEP20074267B (fr)
HK (2) HK1059283A1 (fr)
HU (1) HU227331B1 (fr)
IL (3) IL154622A0 (fr)
IS (1) IS6729A (fr)
MX (1) MXPA03002328A (fr)
NO (2) NO332318B1 (fr)
NZ (1) NZ525187A (fr)
PL (1) PL207267B1 (fr)
PT (2) PT1842918E (fr)
RS (1) RS50728B (fr)
SK (1) SK4712003A3 (fr)
TW (1) TWI322181B (fr)
UA (1) UA83458C2 (fr)
WO (1) WO2002024909A2 (fr)
ZA (1) ZA200301903B (fr)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
EP0878552A1 (fr) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Détection moléculaire d'aberration chromosomique
JP2002513587A (ja) * 1998-05-04 2002-05-14 ダコ エー エス 染色体異常を検出するための方法およびプローブ
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
PL207501B1 (pl) 1999-08-17 2010-12-31 Apotech R & D Sa Zastosowanie polipeptydu BCMA oraz przeciwciała skierowanego przeciwko BCMA
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
DE60028830T2 (de) * 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco Anti-april antikörper und hybridomazellen
ATE494304T1 (de) 2000-06-16 2011-01-15 Human Genome Sciences Inc Immunspezifisch bindende antikörper gegen blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
EP2184291A1 (fr) 2000-08-18 2010-05-12 Dyax Corp. Polypeptides de liaison pour protéine stimulatrice des lymphocytes B (BLyS)
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CA2428242A1 (fr) * 2000-11-07 2002-05-16 Zymogenetics, Inc. Recepteur humain de facteur de necrose tumorale
WO2002072827A1 (fr) * 2001-02-28 2002-09-19 Riken Recepteur specifique de cellule b se liant a traf3
EA007984B1 (ru) * 2001-08-03 2007-02-27 Дженентек, Инк. ПОЛИПЕПТИДЫ TACIs И BR3 И ИХ ПРИМЕНЕНИЕ
US7112410B1 (en) * 2001-08-29 2006-09-26 Human Genome Sciences, Inc. Human tumor necrosis factor TR21 and methods based thereon
AU2002339680A1 (en) * 2001-12-26 2003-07-15 Genset S.A. Agonists and antagonists of bromix for the treatment of metabolic disorders
WO2003072713A2 (fr) * 2002-02-21 2003-09-04 Biogen Idec Ma Inc. Utilisation de bcma comme agent immunoregulateur
AU2003225093A1 (en) * 2002-04-22 2003-11-03 Fred Hutchinson Cancer Research Center Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
CA2524892A1 (fr) * 2002-05-17 2003-11-27 Retrovec Aps Polypeptide purifie, acides nucleiques isoles le codant, vecteurs et utilisation correspondante
AU2003256836A1 (en) * 2002-07-25 2004-02-16 Genentech, Inc. Taci antibodies and uses thereof
JP5524441B2 (ja) 2003-03-28 2014-06-18 バイオジェン・アイデック・エムエイ・インコーポレイテッド 短縮されたｂａｆｆレセプター
PT1631313E (pt) 2003-06-05 2015-07-02 Genentech Inc Terapêutica de combinação para distúrbios de células b
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
KR20070001880A (ko) * 2003-10-20 2007-01-04 바이오겐 아이덱 엠에이 인코포레이티드 Ｂαｆｆ 길항제를 위한 치료 섭생법
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
WO2005075511A1 (fr) 2004-01-29 2005-08-18 Genentech, Inc. Variants du domaine extracellulaire de bcma et utilisations de ceux-ci
CA2567520A1 (fr) 2004-06-01 2005-12-15 Genentech, Inc. Conjugues anticorps-maytansinoides
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP3088004B1 (fr) 2004-09-23 2018-03-28 Genentech, Inc. Anticorps et conjugués modifiés au niveau des cystéines
JP2008526205A (ja) * 2004-12-31 2008-07-24 ジェネンテック・インコーポレーテッド Ｂｒ３に結合するポリペプチド及びその使用
CA2596276A1 (fr) * 2005-01-28 2006-08-03 Biogen Idec Ma Inc. Utilisation de baff pour traiter des pathologies induites par th2
NZ568204A (en) 2005-10-13 2012-01-12 Human Genome Sciences Inc Methods and compositions for use in treatment of patients with autoantibody positive diseases
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
PL2446904T3 (pl) 2006-05-30 2015-10-30 Genentech Inc Przeciwciała anty-CD22, ich immunokoniugaty oraz ich zastosowania
WO2008008482A2 (fr) * 2006-07-13 2008-01-17 Genentech, Inc. Polypeptides de liaison à br3 modifiés
ES2565202T3 (es) 2007-10-16 2016-04-01 Zymogenetics, Inc. Combinación de activador transmembrana y modulador de calcio e interactor de ligando de ciclofilina (TACI) y agentes anti-CD20 para tratamiento de enfermedades autoinmunitarias
BRPI0817182A2 (pt) 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
WO2010007082A1 (fr) 2008-07-17 2010-01-21 Novartis Ag Compositions et procédés d'utilisation pour des anticorps thérapeutiques
ES2749190T3 (es) 2008-08-14 2020-03-19 Genentech Inc Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas indígenas
JP5705115B2 (ja) 2008-09-10 2015-04-22 ジェネンテック， インコーポレイテッド 蛋白質の酸化的分解の予防のための組成物および方法
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
CN104877026B (zh) 2009-03-10 2019-10-25 比奥根Ma公司 抗-bcma抗体
US8728730B2 (en) 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
EP2475391B1 (fr) 2009-09-09 2018-09-12 Centrose, LLC Conjugués médicamenteux ciblés à visée extracellulaire
WO2011109280A1 (fr) 2010-03-05 2011-09-09 Lerner Research Institute Procédés et compositions permettant de traiter les troubles d'origines immunes
CA2792125C (fr) 2010-03-22 2019-02-12 Genentech, Inc. Compositions et procedes utiles pour stabiliser les formulations contenant des proteines
CN102933236B (zh) 2010-04-15 2014-10-08 斯皮罗根有限公司 吡咯并苯二氮卓类及其结合物
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
ES2684921T3 (es) 2010-05-10 2018-10-05 Intas Pharmaceuticals Limited Formulación líquida de polipéptidos que contienen un dominio Fc de una inmunoglobulina
CN101851278B (zh) * 2010-05-26 2013-03-13 石药集团中奇制药技术（石家庄）有限公司 B细胞激活因子拮抗剂及其制备方法与用途
CN103068406B (zh) 2010-06-08 2017-06-30 基因泰克公司 半胱氨酸改造的抗体和偶联物
CA3111727C (fr) 2010-06-24 2022-07-26 Genentech, Inc. Compositions et methodes pour stabiliser des preparations contenant des proteines
CN103313990B (zh) 2010-11-17 2016-07-20 基因泰克公司 丙氨酰美登醇抗体偶联物
US8735347B2 (en) 2011-02-02 2014-05-27 Children's Hospital Medical Center Regulation of energy metabolism and obesity by modulating B cell activating factor (BAFF, BLYS) or BAFF signaling
RU2013140975A (ru) 2011-02-28 2015-04-10 Дженентек, Инк. Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
CN103608684B (zh) 2011-05-12 2016-05-04 基因泰克公司 利用框架签名肽检测动物样品中的治疗性抗体的多重反应监测lc-ms/ms方法
HUE025661T2 (en) 2011-10-14 2016-04-28 Medimmune Ltd Pyrrolobenzodiazepines and their conjugates
SG10201604896TA (en) * 2011-12-16 2016-08-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
CA2859376C (fr) 2011-12-22 2022-04-19 Genentech, Inc. Utilisation de la chromatographie par echange d'ions pour ameliorer les etapes de chromatographie en aval dans la purification d'anticorps
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
KR101995620B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
RS57694B1 (sr) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pirolobenzodiazepin - anti-psma konjugati antitela
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
NZ707490A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
MX364329B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
WO2014096365A1 (fr) 2012-12-21 2014-06-26 Spirogen Sàrl Dimères de pyrrolobenzodiazépines asymétriques à utiliser dans le traitement de maladies prolifératives et auto-immunes
EP2935268B2 (fr) 2012-12-21 2021-02-17 MedImmune Limited Pyrrolobenzodiazépines et conjugués associés
EP2968596B1 (fr) 2013-03-13 2019-03-06 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
CA2904044C (fr) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines et leurs conjugues
CA2918139A1 (fr) 2013-08-12 2015-02-19 Genentech, Inc. Conjugues anticorps-medicament dimerique 1-(chloromethyl)-2,3-dihydro-1 h-benzo [e]indole, et methodes d'utilisation et de traitement
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054985B1 (fr) 2013-10-11 2018-12-26 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
WO2015052535A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
KR20170042495A (ko) 2013-12-16 2017-04-19 제넨테크, 인크. 펩티드모방체 화합물 및 그의 항체-약물 접합체
WO2015095212A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
WO2015095223A2 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
US10435474B2 (en) 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
WO2016003876A1 (fr) 2014-07-03 2016-01-07 Oklahoma Medical Research Foundation Traitement de la sclerose en plaque et de la neuromyelite optique
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
EP3191134B1 (fr) 2014-09-12 2019-11-20 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
MA40575A (fr) 2014-09-17 2016-03-24 Genentech Inc Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN107206101B (zh) 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017165734A1 (fr) 2016-03-25 2017-09-28 Genentech, Inc. Dosage multiplexé pour la quantification d'anticorps totaux et de médicaments conjugués à des anticorps
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (fr) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Conjugués anticorps-protac et procédés d'utilisation
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
EP3464280B1 (fr) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
ES2871001T3 (es) 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
JP2020517609A (ja) 2017-04-18 2020-06-18 メディミューン リミテッド ピロロベンゾジアゼピン複合体
BR112019021880A2 (pt) 2017-04-20 2020-06-02 Adc Therapeutics Sa Terapia de combinação com conjugado anticorpo anti-axl-droga
US11512114B2 (en) 2017-05-09 2022-11-29 Cyano Biotech Gmbh Modified microcystins and nodularins
AU2018278678B2 (en) 2017-05-09 2022-02-03 Cyano Biotech Gmbh Method for modifying microcystins and nodularins
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
RS62928B1 (sr) 2017-08-18 2022-03-31 Medimmune Ltd Konjugati pirolobenzodiazepina
MX2020003089A (es) 2017-09-20 2020-10-15 Ph Pharma Co Ltd Analogos de tailanstatina.
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
US12116415B2 (en) 2018-10-09 2024-10-15 Single Cell Technology, Inc. Anti-BCMA antibodies
CA3115110A1 (fr) 2018-10-24 2020-04-30 F. Hoffmann-La Roche Ag Inducteurs chimiques conjugues de degradation et methodes d'utilisation
EP3894427A1 (fr) 2018-12-10 2021-10-20 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
EP3946457A1 (fr) 2019-04-01 2022-02-09 Genentech, Inc. Compositions et procédés de stabilisation de formulations contenant des protéines
WO2022027037A1 (fr) 2020-07-27 2022-02-03 Single Cell Technology, Inc. Anticorps anti-protéine de spicule du sars coronavirus‑2
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
US20240360181A1 (en) * 2021-05-20 2024-10-31 Achelois Biopharma, Inc. Compositions and methods for multivalent surface display on enveloped particles
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations
WO2024182541A1 (fr) * 2023-02-28 2024-09-06 Mayo Foundation For Medical Education And Research Molécules se liant à des polypeptides du récepteur du facteur d'activation des lymphocytes b
WO2024220546A2 (fr) 2023-04-17 2024-10-24 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
EP0437576B1 (fr) 1989-07-25 2002-07-03 Cell Genesys, Inc. Recombinaison homologue pour cellules donneuses universelles et hotes mammiferes chimeriques
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5945397A (en) 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
HUT65903A (en) 1990-07-10 1994-07-28 Smithkline Beecham Corp Oxamides, process for preparing them and pharmaceutical compositions containing them
WO1992009689A1 (fr) 1990-12-03 1992-06-11 Stratagene Adn polymerase i thermostable purifiee de $i(pyrococcus furiosus)
WO1993004169A1 (fr) 1991-08-20 1993-03-04 Genpharm International, Inc. Ciblage de genes dans des cellules animales au moyen de produits de synthese d'adn isogeniques
CA2148252C (fr) 1992-10-30 2007-06-12 Roger Brent Systeme de piegeage pour l'isolement de nouvelles proteines
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
DE69320824T2 (de) 1993-12-09 1999-05-12 Stmicroelectronics S.R.L., Agrate Brianza, Mailand/Milano Integrierte Schaltung zur Überwachung der Benutzung von Redunanzspeicherbauelementen in einer Halbleiterspeichereinrichtung
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
DK0897390T3 (da) 1996-03-14 2004-03-08 Human Genome Sciences Inc Human tumornekrosefaktor-delta og -epsilon
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
NZ334309A (en) 1996-10-25 2000-08-25 Human Genome Sciences Inc Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
WO1998027114A2 (fr) 1996-12-17 1998-06-25 Schering Corporation Antigenes de surface mammaliens et reactifs associes
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (fr) 1997-04-02 1998-10-02 Smithkline Beecham Corporation Tl5, homologue tnf
WO1998055621A1 (fr) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf)
WO1998055620A1 (fr) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Element ntn-2 de la famille des ligands du tnf
AU9013998A (en) 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
WO1999011791A2 (fr) 1997-09-05 1999-03-11 University Of Washington Recepteurs et ligands de la famille du facteur de necrose tumorale, acides nucleiques codants et agents de liaison associes
PL339463A1 (en) 1997-09-12 2000-12-18 Biogen April - novel protein of growth promoting action
BR9812433A (pt) 1997-09-12 2000-09-26 Biogen Inc Kay- uma proteìna do sistema de imunização
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
WO2000026244A2 (fr) 1998-11-04 2000-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nouveau membre de la famille des facteurs de necrose des tumeurs, ligand du recepteur de la mort cellulaire (drl) et compositions et procedes correspondants
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
SK288176B6 (sk) 1999-01-07 2014-04-02 Zymogenetics, Inc. Farmaceutický prostriedok obsahujúci fúzny proteín, izolovaná molekula polynukleotidu, expresný vektor, kultivovaná bunka, spôsob prípravy polypeptidu a izolovaný polypeptid
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
DK1415659T3 (da) 1999-01-25 2011-10-03 Biogen Idec Inc BAFF, inhibitorer og anvendelse deraf i modulering af B-cellerespons
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
EP1157110A4 (fr) 1999-02-23 2006-05-10 Human Genome Sciences Inc Neutrokine-alpha et variant d'epissage de neutrokine-alpha
WO2000050633A1 (fr) 1999-02-24 2000-08-31 The General Hospital Corporation Procede de clonage de produits intermediaires de transduction de signaux
WO2000058362A1 (fr) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Nouvelles proteines capables de liaison avec la neutrokine alpha et procedes bases sur lesdites proteines
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
US20030166003A1 (en) 1999-06-14 2003-09-04 Cochran Andrea G. Structured peptide scaffold for displaying turn libraries on phage
PL207501B1 (pl) * 1999-08-17 2010-12-31 Apotech R & D Sa Zastosowanie polipeptydu BCMA oraz przeciwciała skierowanego przeciwko BCMA
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2399387C (fr) 2000-02-11 2015-11-03 Biogen, Inc. Polypeptide heterologue de la famille tnf
ATE494304T1 (de) 2000-06-16 2011-01-15 Human Genome Sciences Inc Immunspezifisch bindende antikörper gegen blys
CA2419661A1 (fr) 2000-08-15 2002-03-07 Guo-Liang Yu Neutrokine-alpha et variant d'epissage de neutrokine-alpha
EP2184291A1 (fr) 2000-08-18 2010-05-12 Dyax Corp. Polypeptides de liaison pour protéine stimulatrice des lymphocytes B (BLyS)
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CA2428242A1 (fr) * 2000-11-07 2002-05-16 Zymogenetics, Inc. Recepteur humain de facteur de necrose tumorale
EP2292655B1 (fr) 2001-05-11 2012-03-14 Amgen SF, LLC Peptides et molécules associées qui sont liées à tall-1
EA007984B1 (ru) 2001-08-03 2007-02-27 Дженентек, Инк. ПОЛИПЕПТИДЫ TACIs И BR3 И ИХ ПРИМЕНЕНИЕ
AU2002330074A1 (en) 2001-09-21 2003-04-01 Amgen Inc. Tall-1 receptor molecules and uses thereof
CA2465268A1 (fr) 2001-10-24 2003-05-01 National Jewish Medical And Research Center Structures tridimensionnelles de tall-1 et de ses recepteurs parents, proteines modifiees et procedes associes
WO2003055979A2 (fr) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Anticorps se liant à blys selon un mode immunospécifique
PT1631313E (pt) 2003-06-05 2015-07-02 Genentech Inc Terapêutica de combinação para distúrbios de células b
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
US20060240520A1 (en) 2006-10-26
YU19903A (sh) 2006-05-25
CN1940068A (zh) 2007-04-04
ES2286139T3 (es) 2007-12-01
WO2002024909A2 (fr) 2002-03-28
US20120070437A1 (en) 2012-03-22
IL154622A (en) 2010-11-30
ZA200301903B (en) 2004-06-25
EA024034B1 (ru) 2016-08-31
AU2001288858A2 (en) 2002-04-02
DE60128002T2 (de) 2008-01-03
PL207267B1 (pl) 2010-11-30
IL154622A0 (en) 2003-09-17
NZ525187A (en) 2006-02-24
TWI322181B (en) 2010-03-21
CN1622995A (zh) 2005-06-01
US20040072188A1 (en) 2004-04-15
PT1842918E (pt) 2012-07-23
EP1842918B1 (fr) 2012-04-18
MXPA03002328A (es) 2003-06-06
EP2325317B2 (fr) 2016-07-27
DK1842918T3 (da) 2012-07-23
KR100935744B1 (ko) 2010-01-06
EE200300107A (et) 2005-02-15
BG66208B1 (bg) 2012-04-30
PT1352063E (pt) 2007-07-11
DK1352063T3 (da) 2007-08-06
CA2422622C (fr) 2010-11-16
RS50728B (sr) 2010-08-31
BR0113921A (pt) 2004-12-14
IL206414A (en) 2012-02-29
AR030760A1 (es) 2003-09-03
UA83458C2 (uk) 2008-07-25
DK2325317T3 (da) 2013-01-07
US7112421B2 (en) 2006-09-26
US20060240519A1 (en) 2006-10-26
US20100311189A1 (en) 2010-12-09
IS6729A (is) 2003-02-28
US20140187485A1 (en) 2014-07-03
KR20030074596A (ko) 2003-09-19
US8524672B2 (en) 2013-09-03
EP2325317A1 (fr) 2011-05-25
BG107621A (bg) 2004-01-30
EP1352063A2 (fr) 2003-10-15
AU8885801A (en) 2002-04-02
US8026072B2 (en) 2011-09-27
JP2014064585A (ja) 2014-04-17
EA200901129A1 (ru) 2010-04-30
CA2422622A1 (fr) 2002-03-28
NO20031248D0 (no) 2003-03-18
HK1158260A1 (en) 2012-07-13
CY1106708T1 (el) 2012-05-23
NO20120869A1 (no) 2014-02-07
US7635677B2 (en) 2009-12-22
US20060240517A1 (en) 2006-10-26
PL366331A1 (en) 2005-01-24
WO2002024909A9 (fr) 2003-04-03
WO2002024909A3 (fr) 2003-07-31
EA012833B1 (ru) 2009-12-30
EP1842918A1 (fr) 2007-10-10
AU2001288858B2 (en) 2007-11-01
ES2388153T3 (es) 2012-10-09
JP5904689B2 (ja) 2016-05-25
NO20031248L (no) 2003-05-16
US7638327B2 (en) 2009-12-29
CN104311658A (zh) 2015-01-28
HUP0401591A2 (hu) 2004-11-29
IL206414A0 (en) 2010-12-30
US20060240518A1 (en) 2006-10-26
EP1842918B2 (fr) 2016-07-27
EA200300381A1 (ru) 2003-10-30
CZ299161B6 (cs) 2008-05-07
ATE360070T1 (de) 2007-05-15
EP2325317B1 (fr) 2012-11-07
US7709220B2 (en) 2010-05-04
SK4712003A3 (en) 2003-10-07
ATE554171T1 (de) 2012-05-15
CY1113421T1 (el) 2016-06-22
JP2004509624A (ja) 2004-04-02
HK1059283A1 (en) 2004-06-25
EP1352063B1 (fr) 2007-04-18
HU227331B1 (en) 2011-03-28
DE60128002D1 (de) 2007-05-31
HUP0401591A3 (en) 2005-05-30
GEP20074267B (en) 2007-12-25
CN1622995B (zh) 2013-09-04
NO332318B1 (no) 2012-08-27

Similar Documents

Publication Publication Date Title
EE05411B1 (et) Retseptori nukleiinhapped ja polpeptiidid
NO20021453D0 (no) Immunstimulerende nukleinsyrer
NO20003303D0 (no) Vaksine
NO20014325L (no) Vaksine
DE60002650D1 (de) Öladjuvierter Impfstoff
NO20020763D0 (no) Vaksine
FR2776928B1 (fr) Vaccins adn adjuves
DE60143490D1 (de) Von oligoolefinen mit funktionellen endgruppen abgeleitete funktionelle substanzen
EE200200096A (et) IREN-valk, selle valmistamine ja kasutamine
NO20013933D0 (no) Peptider
EE200200168A (et) PRV-1-geen ja selle kasutamine
DE50113285D1 (de) Spann-und Stützelement
AU7005801A (en) Gp354 nucleic acids and polypeptides
AU2001268060A1 (en) G-protein coupled receptor proteins and nucleic acids encoding same
AU7298201A (en) Gp286 nucleic acids and polypeptides
SE0102061D0 (sv) New proteins and the corresponding DNA sequences
DE60041090D1 (de) Sekretierte Transmembranproteine und dafür kodierende Nukleinsäuren
SE9801035D0 (sv) New DNA sequences and proteins
FI20001811A0 (fi) Laituri ja paalu
IT1312568B1 (it) Peptidi immunogenici e loro uso.
GB0122304D0 (en) Proteins and nucleic acids
GB0107627D0 (en) Proteins and nucleic acids
AU1663702A (en) Proteins and nucleic acids encoding same
AU2002246696A8 (en) Proteins and nucleic acids encoding same
ID30211A (id) Protein baru dan penggunaannya

Legal Events

Date Code Title Description
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20160906